Desensitization to biological agents used in rheumatology

Biological agents such as monoclonal antibodies and fusion proteins are widely used for the treatment of patients with various rheumatic disorders, influencing the quality of life, disability and even mortality in patients. However, biological agents can evoke adverse reactions of different grades o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joanna Makowska, Anna Lewandowska-Polak
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2020
Materias:	drug hypersensitivity desensitization biological agents rheumatic diseases Medicine R
Acceso en línea:	https://doaj.org/article/4a98b33c825846228dec3147539a23bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4a98b33c825846228dec3147539a23bb
record_format	dspace
spelling	oai:doaj.org-article:4a98b33c825846228dec3147539a23bb2021-12-02T17:46:04ZDesensitization to biological agents used in rheumatology0034-62332084-983410.5114/reum.2020.93510https://doaj.org/article/4a98b33c825846228dec3147539a23bb2020-02-01T00:00:00Zhttps://www.termedia.pl/Desensitization-to-biological-agents-used-in-rheumatology,18,40055,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834Biological agents such as monoclonal antibodies and fusion proteins are widely used for the treatment of patients with various rheumatic disorders, influencing the quality of life, disability and even mortality in patients. However, biological agents can evoke adverse reactions of different grades of severity. Although drug avoidance remains a gold standard in the care of patients hypersensitive to medication, in certain clinical situations the culprit drug is the drug of choice and cannot be replaced by another equally effective compound. In such cases, desensitization can allow the patient to be treated within current guidelines and with the most effective treatment. The authors searched Medline and Scopus databases for English-language sources using the following key words: hypersensitivity, desensitization, biologicals, adalimumab, etanercept, adalimumab, certolizumab, golimumab, rituximab, infliximab, ixekizumab, tocilizumab, anakinra and canakinumab. The aim of our review is to present the current knowledge about desensitization to biological agents and some guidelines according to patient inclusion, contraindications, procedures, and safety requirements. Drug desensitization is a new issue in rheumatology, and the solution to the problem of allergic reactions to biological drugs, which gives patients with rheumatic diseases the opportunity to extend and prolong their therapy. The present article is one of the first widely discussing this topic in the biological treatment of rheumatic diseases.Joanna MakowskaAnna Lewandowska-PolakTermedia Publishing Housearticledrug hypersensitivity desensitization biological agents rheumatic diseasesMedicineRENRheumatology, Vol 58, Iss 1, Pp 26-33 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	drug hypersensitivity desensitization biological agents rheumatic diseases Medicine R
spellingShingle	drug hypersensitivity desensitization biological agents rheumatic diseases Medicine R Joanna Makowska Anna Lewandowska-Polak Desensitization to biological agents used in rheumatology
description	Biological agents such as monoclonal antibodies and fusion proteins are widely used for the treatment of patients with various rheumatic disorders, influencing the quality of life, disability and even mortality in patients. However, biological agents can evoke adverse reactions of different grades of severity. Although drug avoidance remains a gold standard in the care of patients hypersensitive to medication, in certain clinical situations the culprit drug is the drug of choice and cannot be replaced by another equally effective compound. In such cases, desensitization can allow the patient to be treated within current guidelines and with the most effective treatment. The authors searched Medline and Scopus databases for English-language sources using the following key words: hypersensitivity, desensitization, biologicals, adalimumab, etanercept, adalimumab, certolizumab, golimumab, rituximab, infliximab, ixekizumab, tocilizumab, anakinra and canakinumab. The aim of our review is to present the current knowledge about desensitization to biological agents and some guidelines according to patient inclusion, contraindications, procedures, and safety requirements. Drug desensitization is a new issue in rheumatology, and the solution to the problem of allergic reactions to biological drugs, which gives patients with rheumatic diseases the opportunity to extend and prolong their therapy. The present article is one of the first widely discussing this topic in the biological treatment of rheumatic diseases.
format	article
author	Joanna Makowska Anna Lewandowska-Polak
author_facet	Joanna Makowska Anna Lewandowska-Polak
author_sort	Joanna Makowska
title	Desensitization to biological agents used in rheumatology
title_short	Desensitization to biological agents used in rheumatology
title_full	Desensitization to biological agents used in rheumatology
title_fullStr	Desensitization to biological agents used in rheumatology
title_full_unstemmed	Desensitization to biological agents used in rheumatology
title_sort	desensitization to biological agents used in rheumatology
publisher	Termedia Publishing House
publishDate	2020
url	https://doaj.org/article/4a98b33c825846228dec3147539a23bb
work_keys_str_mv	AT joannamakowska desensitizationtobiologicalagentsusedinrheumatology AT annalewandowskapolak desensitizationtobiologicalagentsusedinrheumatology
_version_	1718379526861357056

Desensitization to biological agents used in rheumatology

Ejemplares similares